- Home
- SHOE vs AUTL Comparison
SHOE vs AUTL Comparison
Compare SHOE & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SHOE | AUTL |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United Kingdom |
| Employees | 5000 | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 433.9M | 385.9M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | SHOE | AUTL |
|---|---|---|
| Price | $15.10 | $1.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 791.5K | ★ 1.2M |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | N/A | $80.32 |
| Revenue Next Year | N/A | $53.96 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $14.00 | $1.18 |
| 52 Week High | $16.29 | $2.60 |
Technical Indicators
Market Signals| Indicator | SHOE | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 47.67 | 46.79 |
| Support Level | $14.29 | $1.37 |
| Resistance Level | $15.89 | $1.52 |
| Average True Range (ATR) | 0.65 | 0.10 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 52.57 | 28.77 |
Price Performance
Historical ComparisonAbout SHOE Shoe Station Group Inc. Common Stock
Shoe Station Group Inc is a one-stop family footwear destination that offers an impressive selection from top brands. It is a fashion destination for footwear, southern-inspired accessories, and apparel. The group has physical stores throughout five Southern states and is available online at ShoeStation.com, shipping all across the U.S. Its offer products for Women's, Men's, and Kids.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.